IP Library Patent Application 16360583
Patent Application
App. No. 16/360,583

METHODS OF TREATING TESTOSTERONE DEFICIENCY

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/360,583
Abstract

Methods of treating a testosterone deficiency or its symptoms with a pharmaceutical formulation of testosterone esters are provided. The methods are designed to provide optimum serum testosterone levels over an extended period.

Claims (15)

1 .- 24 . (canceled)

25 . A method of treating chronic testosterone deficiency in a subject in need thereof comprising the steps of:

a. administering daily to a subject in need thereof an oral pharmaceutical composition comprising about 475 mg of testosterone undecanoate solubilized in a carrier comprising oleic acid, polyoxyethyelene (40) hydrogenated castor oil, borage seed oil, and peppermint oil:

b. measuring the serum testosterone concentration in the subject three to five hours following the daily administration of the oral pharmaceutical composition; and

c. increasing the dose of testosterone ester administered in step a. when the measured serum testosterone concentration in the subject is less than about 250 ng/dL, decreasing each dose of testosterone ester administered in step a. when the measured serum testosterone concentration in the subject is greater than about 700 ng/dL, and maintaining each dose of testosterone ester administered in step a. when the measured serum testosterone concentration in the subject is between about 250 ng/dL and about 700 ng/dL;

wherein steps a.-c. are repeated until the serum testosterone concentration in the subject is between about 250 and about 700 ng/dL; and

wherein the serum testosterone concentration is measured after seven days of daily treatment with the oral pharmaceutical composition.

26 . The method of claim 25 , wherein the oral pharmaceutical composition is administered twice daily.

27 . The method of claim 25 , wherein, once steady-state is achieved, the serum testosterone response does not decline over time.

28 . The method of claim 25 , wherein said oral pharmaceutical composition comprises:

a) 15-20 percent by weight of solubilized testosterone undecanoate;

b) 5-20 percent by weight hydrogenated castor oil ethoxylate;

c) 30-70 percent by weight of oleic acid; and

d) 10-15 percent by weight of digestible oil.

29 . The method of claim 25 , wherein said oral pharmaceutical composition is administered in one or more capsules.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Dec 6, 2022
From: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS SUCCESSOR TO U.S. BANK NATIONAL ASSOCIATION
To: CLARUS THERAPEUTICS, INC.
Reel/Frame 062000/0052 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 15, 2022
From: CLARUS THERAPEUTICS, INC.
To: TOLMAR, INC.
Reel/Frame 061774/0516 →
SECURITY INTEREST Recorded Mar 12, 2020
From: CLARUS THERAPEUTICS, INC.
To: U.S. BANK NATIONAL ASSOCIATION
Reel/Frame 052099/0349 →